PI(4)K Inhibitor Could Prove Cure For Killer Diarrhoea
Cryptosporidium parvum. Credit: EPA/H.D.A. Lindquist
Infectious disease scientists from Novartis, the University of Georgia and Washington State University have reported the discovery and early validation of a drug candidate for treating cryptosporidiosis, a diarrheal disease which is a major cause of child mortality in lower-income countries. Currently there are no vaccines or effective treatments.
"There's a lot of uncertainty when embarking on drug discovery for a notoriously intractable parasite such as Cryptosporidium, the cause of cryptosporidiosis," said Thierry Diagana, Head of the Novartis Institute for Tropical Diseases (NITD). "Thanks to the commitment of our funding collaborators and urgent action of our academic colleagues, we've made an important step toward advancing a new treatment."
Diarrheal diseases cause more than 800,000 deaths annually1. Epidemiological studies have highlighted the vital need for new treatment options against the protozoan parasite Cryptosporidium, which often infects its victims from exposure to contaminated water supplies. Nitazoxanide, the only approved treatment for cryptosporidiosis, has shown poor results in vulnerable infants and immune-compromised patients2,3.
Yet there are obstacles to finding new treatments. The parasite perishes relatively quickly in labs and scientists have lacked research tools to identify drug candidates. The team developed a novel drug discovery process using transgenic parasites and novel disease models, leading to the identification and validation of the Cryptosporidium PI(4)K inhibitor candidate KDU731. They reported the discovery and preclinical findings in a recent issue of Nature4.
Novartis is advancing research of cryptosporidiosis through collaborations with the global health community and its scientists at NITD, which is ramping up its research and operations in Emeryville, CA.
1. Liu, L. et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. The Lancet. 2016.
2. Amadi, B. et al. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC infectious diseases. 2009.
3. Amadi, B. et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. The Lancet. 2002
4. Manjunatha, U., Vinayak, S., Zambriski, J., Chao, A., Sy, T., Noble, C., Bonamy, G., Kondreddi, R., Zou, B., Gedeck, P., Brooks, C., Herbert, G., Sateriale, A., Tandel, J., Noh, S., Lakshminarayana, S., Lim, S., Goodman, L., Bodenreider, C., Feng, G., Zhang, L., Blasco, F., Wagner, J., Leong, F., Striepen, B. and Diagana, T. (2017). A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis. Nature.
This article has been republished from materials provided by Novartis. Note: material may have been edited for length and content. For further information, please contact the cited source.
Screening for Disease or Toxins in a Drop of BloodNews
Scientist have developed a multinozzle emitter array (MEA), a silicon chip that can dramatically shorten the time it takes to identify proteins, peptides, and other molecular components within small volumes of biological samples.READ MORE
Phenogenetic Map Created For Stem Cell Models Of Neurological DiseasesNews
Researchers at The Ohio State University Wexner Medical Center have performed the first meta-analysis of all induced pluripotent stem cell models for neurological and neurodegenerative diseases, and created an atlas of how cell characteristics are linked to their genotype.READ MORE
Diabetic Ketoacidosis Assay Collaboration Between Ortho Clinical Diagnostics and EKF DiagnosticsNews
EKF’s Beta-Hydroxybutyrate LiquiColor® Assay for detection of predominant ketone body now available on Ortho’s VITROS® 4600 Chemistry System and VITROS® 5600 Integrated System.READ MORE